[go: up one dir, main page]

MX2012002752A - Compuestos de heteroarilo como inhibidores de cinasa. - Google Patents

Compuestos de heteroarilo como inhibidores de cinasa.

Info

Publication number
MX2012002752A
MX2012002752A MX2012002752A MX2012002752A MX2012002752A MX 2012002752 A MX2012002752 A MX 2012002752A MX 2012002752 A MX2012002752 A MX 2012002752A MX 2012002752 A MX2012002752 A MX 2012002752A MX 2012002752 A MX2012002752 A MX 2012002752A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
heteroaryl compounds
compound
formula
heteroaryl
Prior art date
Application number
MX2012002752A
Other languages
English (en)
Inventor
Martin Sendzik
Keith B Pfister
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2012002752A publication Critical patent/MX2012002752A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I): (ver fórmula (I)) y las sales farmacéuticamente aceptables del mismo. También se proporciona un método para utilizar un compuesto de la fórmula l para el tratamiento de una enfermedad o condición mediada por un inhibidor de CDK.
MX2012002752A 2009-09-04 2010-09-02 Compuestos de heteroarilo como inhibidores de cinasa. MX2012002752A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27593909P 2009-09-04 2009-09-04
PCT/EP2010/062908 WO2011026917A1 (en) 2009-09-04 2010-09-02 Heteroaryl compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2012002752A true MX2012002752A (es) 2012-04-19

Family

ID=43532948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002752A MX2012002752A (es) 2009-09-04 2010-09-02 Compuestos de heteroarilo como inhibidores de cinasa.

Country Status (9)

Country Link
US (1) US20120157433A1 (es)
EP (1) EP2473502A1 (es)
KR (1) KR20120049940A (es)
CN (1) CN102498107A (es)
AU (1) AU2010291212A1 (es)
BR (1) BR112012008147A2 (es)
CA (1) CA2771568A1 (es)
MX (1) MX2012002752A (es)
WO (1) WO2011026917A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130016244A (ko) * 2010-03-10 2013-02-14 인게니움 파르마코이티칼스 게엠베하 단백질 키나아제의 억제제
WO2012066065A1 (en) * 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
WO2012101064A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
ES2587284T3 (es) 2011-09-16 2016-10-21 Bayer Intellectual Property Gmbh 5-Fluoro-pirimidinas 2,4-disustituidas como inhibidores selectivos de CDK9
CN104854091B (zh) 2012-10-18 2018-04-03 拜耳药业股份公司 含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物
ES2597232T3 (es) 2012-10-18 2017-01-17 Bayer Pharma Aktiengesellschaft 4-(orto)-fluorofenil-5-fluoropirimidin-2-il aminas que contienen un grupo sulfona
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
JPWO2015037716A1 (ja) 2013-09-12 2017-03-02 住友化学株式会社 含窒素飽和複素環化合物
WO2016059011A1 (en) 2014-10-16 2016-04-21 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
MY201673A (en) * 2015-06-29 2024-03-12 Astrazeneca Ab Polycyclic amide derivatives as cdk9 inhibitors
CN108290903B (zh) 2015-09-29 2021-09-03 拜耳医药股份有限公司 新的大环磺酰二亚胺化合物
US10214542B2 (en) 2015-10-08 2019-02-26 Bayer Pharma Aktiengesellschaft Modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
MA51820A (fr) 2018-02-13 2021-05-19 Bayer Ag Utilisation de 5-fluoro-4-(4-fluoro-2-méthoxyphényl)-n-(4-[(s-méthylsulfonimidoyl)méthyl]pyridin-2-yl)pyridin-2-amine pour traiter un lymphome diffus à grandes cellules b
TWI834637B (zh) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
CN112574181B (zh) * 2019-09-30 2024-11-22 天津药业研究院股份有限公司 苏沃雷生中间体的制备方法及应用
CN114787142B (zh) * 2019-12-09 2024-08-02 石药集团中奇制药技术（石家庄）有限公司 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用
AU2021279023A1 (en) * 2020-05-27 2022-12-15 Constellation Pharmaceuticals, Inc. Substituted benzamides as modulators of TREX1
IL300208A (en) 2020-08-05 2023-03-01 Richter Gedeon Nyrt Pharmacologically active heterocyclic substituted pyrazolo[5,1-a]pyrimidine derivatives
CN115381824B (zh) * 2021-05-24 2024-11-05 石药集团中奇制药技术（石家庄）有限公司 周期蛋白依赖性激酶9抑制剂的用途
WO2022247785A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
WO2022257965A1 (zh) * 2021-06-09 2022-12-15 石药集团中奇制药技术（石家庄）有限公司 固体形式的周期蛋白依赖性激酶9抑制剂及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US20020052370A1 (en) * 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
AR036053A1 (es) * 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
SE0301963D0 (sv) * 2003-07-02 2003-07-02 Astrazeneca Ab New compounds
WO2007018319A1 (ja) * 2005-08-11 2007-02-15 Takeda Pharmaceutical Company Limited ピリジルフェノール化合物およびその用途
WO2009002933A1 (en) * 2007-06-22 2008-12-31 Hydra Biosciences, Inc. Methods and compositions for treating disorders

Also Published As

Publication number Publication date
EP2473502A1 (en) 2012-07-11
WO2011026917A1 (en) 2011-03-10
BR112012008147A2 (pt) 2016-03-01
CA2771568A1 (en) 2011-03-10
KR20120049940A (ko) 2012-05-17
AU2010291212A1 (en) 2012-02-23
CN102498107A (zh) 2012-06-13
US20120157433A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
MX2012002752A (es) Compuestos de heteroarilo como inhibidores de cinasa.
IN2012DN01273A (es)
WO2011123946A8 (en) Kinase inhibitors and method of treating cancer with same
MX2012002761A (es) Bipiridinas utiles para el tratamiento de enfermedades proliferativas.
WO2010151710A3 (en) Substituted heterocyclic compounds as kinases inhibitors and method of use thereof
MX2011009796A (es) Inhibidores de la cinasa pi3.
UA99361C2 (uk) ТРИАЗИНИ ЯК ІНГІБІТОРИ PІ3-КІНАЗИ І mTOR
MX2012015098A (es) Compuestos heterociclicos fusionados como inhibidores de fosfodiesterasas (pdes).
MD4582B1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
TN2011000400A1 (en) Inhibitors of beta-secretase
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
JO2885B1 (en) Protein kinase inhibitors
WO2010135524A8 (en) Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
WO2012068096A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
UA105794C2 (uk) 1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
MX2009006630A (es) Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa.
WO2010014930A3 (en) Piperidine derivatives as jak3 inhibitors
WO2012068106A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2010144499A3 (en) Urea derivatives as kinase inhibitors
GEP20125708B (en) Hydroxamate-based inhibitors of deacetylases b
UA105527C2 (uk) Сполука-інгібітор матриптази для лікування раку
MX347619B (es) Polimorfos y sales de 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-p iperazinil] metil}-1,3-oxazol-2-il)-1h-indazol como inhibidores de pi3k para usarse por ejemplo en el tratamiento de trastornos respiratorios.
EA201270816A1 (ru) Производные бензамида и их применение в качестве ингибиторов hsp90
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
WO2010123545A3 (en) Angiogenesis inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal